--- the subscriber area has no ads and those above are not selected or endorsed by this site ---
Resonant shipments & 3Q19 schedule plus EMAN & AUO ?3
09:08 21-Oct-19
Resonant
has scheduled its third quarter report for the evening of November
5th. The average of estimates from 5 analysts comes to a loss of
20 cents from revenue of $334K, increasing to $620K this quarter.
However, in its press
release, management chose instead to highlight royalty unit
shipments in the third quarter have exceeded those for the first
half, and that royalty revenue increased sequentially.
I don't see that as a big accomplishment, since second quarter revenue was a disappointing $63K. RESN hasn't traded in the pre-market, and there is potential for a sling-shot effect from depressed valuation. However, I think that waiting for year-end tax-loss selling has at least as good a chance of getting the best priced entry point. Those who feel they have insufficient current positions and are prone to fear of missing out, might consider splitting any accumulation.
It can be even harder to keep the long-term prospects in mind
when it comes to GRoDT stocks, but that's what informed my
decision to liquidate
AUO when I did. It has now delisted
its shares from NYSE and only trades OTC in America. Expect that
section to move to the public side of the website before
year-end. The same eventual fate probably awaits EMAN, which has
scheduled
its third quarter report for the morning of November 7th. Only
two analysts still cover the company and they expect the company
to lose a penny or two per share from about $7M in sales, with no
guesses on how those will proceed. As predicted
long ago,
eMagin has implemented
cost-cutting measures and is preparing for a
reverse split. Don't expect to hear more from me about them
unless there is some surprise.